Tyra Biosciences, Inc.

NASDAQ:TYRA

Biotechnology

Healthcare
$19.61 -2.48%

-$0.72 today

Market cap
$1.35B
Beta
0.75
P/E (TTM)
-13.4
EPS (TTM)
-$2.12
52W Low $8.98High $40.65

Volume 0.47M

Average 0.96M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$95.14M

FY 2025 · Annual

Investing Cash Flow

$72.46M

FY 2025 · Annual

Financing Cash Flow

$8.10M

FY 2025 · Annual

-96.0% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.29M)(55.33M)(69.13M)(86.48M)(119.95M)
Depreciation & Amortization140K296K357K519K546K
Deferred Income Tax00000
Stock-Based Compensation2.89M10.59M13.53M22.8M28.01M
Change in Working Capital(481K)(5.85M)6.36M(729K)(1.63M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.49M0000
Other Working Capital(1.97M)(5.85M)6.36M(729K)(1.63M)
Other Non-Cash Items3K3K(1.25M)(5.88M)(2.12M)
Operating Cash Flow(23.75M)(50.29M)(50.14M)(69.77M)(95.14M)
Capital Expenditures(661K)(559K)(770K)(664K)(141K)
Acquisitions (Net)16K0000
Purchases of Investments00(143.84M)(263.62M)(101.25M)
Sales of Investments000165.89M173.86M
Other Investing Activities160000
Investing Cash Flow(645K)(559K)(144.61M)(98.4M)72.46M
Debt Repayment(9K)0000
Common Stock Issued181.22M632K1.54M200M8.1M
Common Stock Repurchased000(420K)0
Dividends Paid00000
Other Financing Activities514K002.56M0
Financing Cash Flow311.35M632K1.54M202.14M8.1M
Effect of Forex Changes0(757K)000
Net Change in Cash286.96M(50.97M)(193.21M)33.96M(14.58M)
Free Cash Flow(24.41M)(50.84M)(50.91M)(70.44M)(95.28M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$119.9M
+ D&A$546.0K
+ Stock-Based Comp$28.0M
+ Deferred Tax$0
- Working Capital-$1.6M
- Other Non-Cash-$2.1M
= Operating Cash Flow-$95.1M
- Capex-$141.0K
= Free Cash Flow-$95.3M

Analysis

FY2025 free cash flow is -$95.3M. FCF conversion is 79.4% of net income. Operating cash flow was -$95.1M, with capex of -$141.0K. The largest bridge item is Stock-Based Comp at $28.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
SC 13G/ASC 13G/A filingOct 27, 2026
SC 13GSC 13G filingSep 21, 2026
4Statement of changes in beneficial ownershipSep 17, 2026

Does TYRA generate free cash flow?

Tyra Biosciences, Inc. (TYRA) generated -$95.28M of free cash flow in fiscal 2025.

How much operating cash flow does TYRA produce?

Operating cash flow was -$95.14M, before capital expenditures of $141,000.00.